ALX ONCOLOGY HOLDINGS INC
Income Statement
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | $0 | $0 | $1.2M | $4.8M |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | — | $77.0M | $116.4M | $141.8M | $98.4M | $60.2M | $29.0M | $16.3M |
| SG&A Expense | — | $23.9M | $26.1M | $28.5M | $29.0M | $23.4M | $14.8M | $3.3M |
| Operating Income | — | $-104.0M | $-142.5M | $-170.3M | $-127.4M | $-83.6M | $-43.7M | $-19.2M |
| Operating Margin | — | — | — | — | — | — | -3,694.0% | -400.0% |
| Interest Expense | — | $1.6M | $1.7M | $1.6M | $238.0K | $13.0K | — | — |
| Pretax Income | — | $-101.7M | $-134.9M | $-160.8M | $-123.4M | $-83.5M | $-45.5M | $-19.2M |
| Income Tax Expense | — | $0 | $0 | $0 | $64.0K | $-21.0K | $241.0K | $34.0K |
| Net Income | — | $-101.7M | $-134.9M | $-160.8M | $-123.5M | $-83.5M | $-45.7M | $-19.2M |
| Net Margin | — | — | — | — | — | — | -3,869.7% | -401.2% |
| EPS (Basic) | — | $-1.90 | $-2.58 | $-3.74 | $-3.03 | $-2.07 | $-1.38 | $-0.63 |
| EPS (Diluted) | — | $-1.90 | $-2.58 | $-3.74 | $-3.03 | $-2.07 | $-1.38 | $-0.63 |
| Shares Outstanding (Basic) | 131.6M | 53.7M | 52.2M | 43.0M | 40.7M | 40.3M | 37.0M | 36.9M |
| Shares Outstanding (Diluted) | 131.6M | 53.7M | 52.2M | 43.0M | 40.7M | 40.3M | 37.0M | 36.9M |
| Dividends Per Share | — | — | — | — | — | — | — | — |